10x Genomics (NASDAQ:TXG) Issues Quarterly Earnings Results

10x Genomics (NASDAQ:TXG) announced its quarterly earnings results on Thursday. The company reported ($0.15) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.12, FiscalAI reports. The firm had revenue of $150.67 million for the quarter, compared to analyst estimates of $147.96 million. 10x Genomics had a negative net margin of 12.18% and a negative return on equity of 9.33%.

Here are the key takeaways from 10x Genomics’ conference call:

• Third-quarter revenue was $150.7 million, up 1% year over year, and 10X raised its 2026 revenue outlook to $625 million–$635 million. Excluding patent-litigation settlement revenue, the range implies 4%–6% growth over 2025.
• Atera commercial shipments began in September, and the company now expects to ship about 50 instruments by year-end, up from its prior estimate of 40. Management cited strong demand, while noting that production, installation, and customer training—not orders—are limiting the pace of rollout.
• Spatial consumables revenue grew 16%, with strong Xenium demand; management expects double-digit spatial consumables growth in Q4 as Atera consumables shipments begin. It said customer interest in Atera’s whole-transcriptome option has exceeded expectations.
• Instrument revenue fell 43% as sales of Chromium, Visium, and Xenium instruments declined, partly reflecting customers waiting for Atera. Gross margin was 75% in Q3, but management expects it to fall to the low-to-mid 60% range in Q4 and to be lower in 2027 as Atera placements make the mix more instrument-heavy.
• Single-cell reaction volumes grew at a double-digit rate, supported by Flex Apex adoption, but single-cell consumables revenue rose only 1%. Management said the lower price per reaction for Apex is weighing on revenue as customers shift toward the platform.

10x Genomics Stock Down 14.0%

NASDAQ:TXG traded down $9.46 during trading hours on Thursday, hitting $58.06. 5,954,404 shares of the company traded hands, compared to its average volume of 3,028,884. The company has a market cap of $7.56 billion, a PE ratio of -98.41 and a beta of 2.03. 10x Genomics has a one year low of $12.80 and a one year high of $102.81. The firm’s 50-day simple moving average is $74.19 and its 200-day simple moving average is $41.22.

Insider Transactions at 10x Genomics

In related news, Director Shehnaaz Suliman sold 5,723 shares of the business’s stock in a transaction dated Tuesday, September 22nd. The stock was sold at an average price of $81.19, for a total value of $464,650.37. Following the sale, the director directly owned 23,792 shares in the company, valued at approximately $1,931,672.48. The trade was a 19.39% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Serge Saxonov sold 25,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 22nd. The stock was sold at an average price of $81.22, for a total transaction of $2,030,500.00. Following the completion of the transaction, the chief executive officer directly owned 1,050,249 shares of the company’s stock, valued at approximately $85,301,223.78. This trade represents a 2.33% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 179,333 shares of company stock worth $11,810,070. Company insiders own 8.84% of the company’s stock.

Wall Street Analyst Weigh In

TXG has been the topic of several recent research reports. Stifel Nicolaus set a $70.00 target price on shares of 10x Genomics in a report on Tuesday, October 13th. Stephens downgraded 10x Genomics from an “overweight” rating to an “equal weight” rating in a research note on Friday, October 23rd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of 10x Genomics in a report on Monday, September 21st. Piper Sandler upped their price objective on shares of 10x Genomics from $47.00 to $80.00 and gave the company a “neutral” rating in a research note on Monday, September 28th. Finally, UBS Group assumed coverage on 10x Genomics in a research note on Wednesday, September 9th. They set a “neutral” rating and a $68.00 target price for the company. Five investment analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, 10x Genomics presently has an average rating of “Hold” and an average price target of $68.00.

10x Genomics Company Profile

10x Genomics, Inc is a life sciences technology company that develops tools for analyzing biological systems at the single-cell and spatial levels. Its technologies are designed to help researchers study gene expression, cellular interactions, tissue organization and other biological processes in greater detail than conventional laboratory methods.

The company’s product portfolio includes the Chromium platform for single-cell analysis, the Visium platform for spatial transcriptomics, and the Xenium platform for high-resolution in situ analysis of tissue samples.